Nuveen
PACB icon

Nuveen’s Pacific Biosciences PACB Stock Holding History

Nuveen’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Sell
1,023,113
-1,927,816
-65% -$2.8M ﹤0.01% 2651
2026
Q1 		$3.9M Buy
2,950,929
+2,102,710
+248% +$3.76M ﹤0.01% 1984
2025
Q4 		$1.59M Buy
848,219
+578,035
+214% +$1.11M ﹤0.01% 2392
2025
Q3 		$346K Hold
270,184
– – ﹤0.01% 3019
2025
Q2 		$335K Hold
270,184
– – ﹤0.01% 3008
2025
Q1 		$319K Hold
270,184
– – ﹤0.01% 3022
2024
Q4 		$494K Hold
270,184
– – ﹤0.01% 2989
2024
Q3 		$459K Hold
270,184
– – ﹤0.01% 3044
2024
Q2 		$370K Sell
270,184
-409,742
-60% -$827K ﹤0.01% 3090
2024
Q1 		$2.55M Buy
679,926
+14,121
+2% +$82.7K ﹤0.01% 2286
2023
Q4 		$6.53M Buy
665,805
+7,057
+1% +$57.7K ﹤0.01% 1826
2023
Q3 		$5.5M Sell
658,748
-4,281
-0.6% -$48.9K ﹤0.01% 1819
2023
Q2 		$8.82M Buy
663,029
+5,231
+0.8% +$63.6K ﹤0.01% 1592
2023
Q1 		$7.62M Sell
657,798
-47,309
-7% -$470K ﹤0.01% 1648
2022
Q4 		$5.77M Sell
705,107
-167,530
-19% -$1.44M ﹤0.01% 1829
2022
Q3 		$5.07M Sell
872,637
-10,278
-1% -$59K ﹤0.01% 1894
2022
Q2 		$3.9M Sell
882,915
-187,388
-18% -$1.14M ﹤0.01% 2109
2022
Q1 		$10.6M Sell
1,070,303
-102,415
-9% -$1.18M ﹤0.01% 1598
2021
Q4 		$24M Sell
1,172,718
-76,841
-6% -$1.85M 0.01% 1108
2021
Q3 		$36.8M Sell
1,249,559
-29,020
-2% -$860K 0.01% 852
2021
Q2 		$44.7M Buy
1,278,579
+160,159
+14% +$4.66M 0.01% 809
2021
Q1 		$37.3M Buy
1,118,420
+280,568
+33% +$9.82M 0.01% 894
2020
Q4 		$21.7M Buy
837,852
+175,450
+26% +$2.98M 0.01% 1207
2020
Q3 		$6.54M Buy
662,402
+101,446
+18% +$584K ﹤0.01% 1781
2020
Q2 		$1.94M Sell
560,956
-12,128
-2% -$41.3K ﹤0.01% 2352
2020
Q1 		$1.75M Buy
573,084
+19,593
+4% +$80.2K ﹤0.01% 2251
2019
Q4 		$2.85M Sell
553,491
-689
-0.1% -$3.5K ﹤0.01% 2269
2019
Q3 		$2.86M Buy
554,180
+12,336
+2% +$69K ﹤0.01% 2244
2019
Q2 		$3.28M Buy
+541,844
New +$3.8M ﹤0.01% 2206

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen's PACB Position: Q2 2026 in Review

Nuveen reduced its Pacific Biosciences (PACB) stake by 65% in Q2 2026, selling an estimated $2.8M and leaving 1,023,113 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2651.

Nuveen first reported a position in PACB in Q2 2019 and has held it in 29 quarters since. The position peaked at $44.7M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Nuveen held 1,023,113 shares of Pacific Biosciences worth $1.72M as of Q2 2026.
  • Nuveen sold 1,927,816 Pacific Biosciences shares in Q2 2026, an estimated $2.8M.
  • Pacific Biosciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2651 holding.
  • Nuveen first reported a position in Pacific Biosciences in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Pacific Biosciences position peaked at $44.7M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.